trimethyl(tetrahydro-2H-pyran-4-yloxy)silane | 1263101-05-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: trimethyl(tetrahydro-2H-pyran-4-yloxy)silane
• 英文别名: trimethyl(oxan-4-yloxy)silane
• CAS: 1263101-05-8
• 化学式: C₈H₁₈O₂Si
• 分子量: 174.315
• InChiKey: FBMIKUHLITXTJI-UHFFFAOYSA-N

物化性质

• 沸点：
  178.4±33.0 °C(Predicted)
• 密度：
  0.91±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.02
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  trimethyl(tetrahydro-2H-pyran-4-yloxy)silane 、 5-(3,3-dimethyl-but-1-ynyl)-3-[(trans-4-methyl-cyclohexanecarbonyl)-(4-oxo-cyclohexyl)-amino]-thiophene-2-carboxylic acid methyl ester 在 三乙基硅烷 、 iron(III) chloride 、 甲醇 、 lithium hydroxide monohydrate 作用下， 以 硝基甲烷 、 四氢呋喃 为溶剂， 反应 7.0h， 以24 mg的产率得到5-(3,3-dimethylbut-1-yn-1-yl)-3-((1r,4R)-4-methyl-N-((1r,4R)-4-((tetrahydro-2H-pyran-4-yl)oxy)cyclohexyl)cyclohexane-1-carboxamido)thiophene-2-carboxylic acid
  参考文献：
  名称：

  Discovery of GS-9669, a Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of Genotype 1 Chronic Hepatitis C Infection

  摘要：

  Investigation of thiophene-2-carboxylic acid HCV NS5B site II inhibitors, guided by measurement of cell culture medium binding, revealed the structure activity relationships for intrinsic cellular potency. The pharmacokinetic profile was enhanced through incorporation of heterocyclic ethers on the N-alkyl substituent. Hydroxyl groups were incorporated to modulate protein binding. Intrinsic potency was further improved through enantiospecific introduction of an olefin in the N-acyl motif, resulting in the discovery of the phase 2 clinical candidate GS-9669. The unexpected activity of this compound against the clinically relevant NS5B M423T mutant, relative to the wild type, was shown to arise from both the N-alkyl substituent and the N-acyl group.

  DOI：

  10.1021/jm401420j
• 作为产物：
  描述：

  四氢吡喃-4-醇 、 三甲基氯硅烷 在 咪唑 作用下， 以 二氯甲烷 为溶剂， 生成 trimethyl(tetrahydro-2H-pyran-4-yloxy)silane
  参考文献：
  名称：

  INHIBITORS OF FLAVIVIRIDAE VIRUSES

  摘要：

  提供的是I式化合物： 及其药用可接受的盐和酯。所提供的化合物、组合物和方法对于治疗黄病毒科病毒感染，特别是丙型肝炎感染，是有用的。

  公开号：

  US20110020278A1

文献信息

• INHIBITORS OF FLAVIVIRIDAE VIRUSES
  申请人：Canales Eda

  公开号：US20110020278A1

  公开（公告）日：2011-01-27

  Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

  提供的是I式化合物： 及其药用可接受的盐和酯。所提供的化合物、组合物和方法对于治疗黄病毒科病毒感染，特别是丙型肝炎感染，是有用的。
• Inhibitors of flaviviridae viruses
  申请人：Canales Eda

  公开号：US08569302B2

  公开（公告）日：2013-10-29

  Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

  提供了式I的化合物及其药学上可接受的盐和酯。所提供的化合物、组合物和方法对治疗黄病毒科病毒感染，特别是丙型肝炎感染具有有用性。
• Discovery of GS-9669, a Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of Genotype 1 Chronic Hepatitis C Infection
  作者：Scott E. Lazerwith、Willard Lew、Jennifer Zhang、Philip Morganelli、Qi Liu、Eda Canales、Michael O. Clarke、Edward Doerffler、Daniel Byun、Michael Mertzman、Hong Ye、Lee Chong、Lianhong Xu、Todd Appleby、Xiaowu Chen、Martijn Fenaux、Ahmad Hashash、Stephanie A. Leavitt、Eric Mabery、Mike Matles、Judy W. Mwangi、Yang Tian、Yu-Jen Lee、Jingyu Zhang、Christine Zhu、Bernard P. Murray、William J. Watkins

  DOI：10.1021/jm401420j

  日期：2014.3.13

  Investigation of thiophene-2-carboxylic acid HCV NS5B site II inhibitors, guided by measurement of cell culture medium binding, revealed the structure activity relationships for intrinsic cellular potency. The pharmacokinetic profile was enhanced through incorporation of heterocyclic ethers on the N-alkyl substituent. Hydroxyl groups were incorporated to modulate protein binding. Intrinsic potency was further improved through enantiospecific introduction of an olefin in the N-acyl motif, resulting in the discovery of the phase 2 clinical candidate GS-9669. The unexpected activity of this compound against the clinically relevant NS5B M423T mutant, relative to the wild type, was shown to arise from both the N-alkyl substituent and the N-acyl group.